Number of ocular and systemic adverse events reported during the study (withdrawn patients included)
| Adverse event | Latanoprost | Timolol-pilocarpine |
| Ocular | (n=39) | (n=94) |
| Ocular discomfort | 33 | 70 |
| Blurred vision | 2 | 54 |
| Decreased visual acuity | 4 | 18 |
| Decreased twilight vision | 1 | 14 |
| Visual field changes/scotoma | 4 | 11† |
| Photophobia | 0 | 9 |
| Eyelid pain and discomfort | 2 | 9 |
| Conjunctival hyperaemia | 7 | 5 |
| Increased IOP | 1 | 3 |
| Punctate corneal erosions | 2 | 0 |
| Conjunctivitis | 1 | 2 |
| Other | 13 | 12 |
| Systemic | (n=11) | (n=36) |
| Headache | 4 | 25 |
| Dizziness | 1 | 4 |
| Influenza | 4 | 1 |
| Vertigo/imbalance | 1† | 4 |
| Nausea | 0 | 1 |
| Other | 3† | 9† |
In parenthesis, n = number of patients reporting adverse events.
↵Ocular discomfort includes burning, itching, tearing, dry eye, stinging, foreign body eye sensation, and eye pain. †Some events reported as serious adverse event, a total of six patients for both treatments groups. Please see text for explanation.